Le Lézard
Classified in: Health
Subject: PER

Dr. Bob Raffa Joins Bridge Therapeutics' Scientific Advisory Board Bring Decades of Research and Experience


BIRMINGHAM, Ala., Sept. 21, 2018 /PRNewswire/ -- Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member.

"We are delighted to have Dr. Raffa join our scientific advisory board. His research on pain and addiction medications will help us develop more effective pain medications with less potential for abuse" says Dr. Dave Bergstrom, Chief Operating Officer of Bridge Therapeutics.

Dr. Raffa is a global leader in pharmacology, with over 40 years of preclinical research on drug abuse and analgesic drug discovery. He has held many prestigious leadership roles, including Co-Leader for analgesic drug discovery at Johnson & Johnson where he attained the level of Research Fellow, as well as being Professor Emeritus at Temple University School of Pharmacy.

Dr. Raffa has published over 300 papers in refereed journals and has published 11 books on topics related to pharmacology, pain, and drug abuse.  He is a Co-Editor of the Journal of Clinical Pharmacy and Therapeutics.  He is a past president of the Mid-Atlantic Pharmacology Society, and he lectures and consults worldwide on analgesics and analgesic combinations.

Bridge Therapeutics' patented lead investigational drug BT-205 is similar to the idea of the centrally-acting opioid/non-opioid analgesic drug Ultracet® for which Dr. Raffa holds a patent. In all, Dr. Raffa holds nine patents on analgesic drugs.

About Bridge Therapeutics

Bridge Therapeutics is an innovative, late development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. Its investigational drug BT-205 is a unique combination of two chronic pain drugs ? the partial-agonist opioid buprenorphine and the NSAID meloxicam ? delivered in a state-of-the-art sublingual formulation. Bridge Therapeutics' goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients experiencing chronic pain.

Ultracet® is a registered trademark of Janssen Pharmaceuticals, Inc., Titusville, New Jersey.

Media Contact:
Alton Kelley
Phone: 877-223-6949
Email: [email protected]

 

SOURCE Bridge Therapeutics


These press releases may also interest you

at 08:16
Canadian health care providers now have access to clinical tools and resources they need to better support older adults experiencing...

at 08:15
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio?quity Europe (12-14 May). The...

at 08:15
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety...

at 08:15
Nuvation Bio Inc. , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms....

at 08:15
Axiom Health, a leading provider of data analytics solutions for the medical device industry, today announced the appointments of Russell "Rusty" Lewis as Chief Executive Officer (CEO) and Jim Best as Chief Commercial Officer (CCO). These...

at 08:15
GlobeStar Therapeutics Corporation (GSTC), is a clinical stage pharmaceutical company focused on advancing new therapies for Multiple Sclerosis (MS) and other neurological diseases, including but not limited to Rheumatoid Arthritis (RA), released on...



News published on and distributed by: